Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Current Pharmaceutical Design, 26 (25), 2971-2981.
Despite promising preclinical data, clinical trials in humans are extremely limited, and the compound remains largely experimental, with ongoing research required to fully characterize pharmacokinetics, optimal dosing, long-term safety, and potential off-target effects
BPC157 specifically bound FBXO22 with a dissociation constant KD of 1.0 10, which was significantly greater than that of the scrambled peptide control (KD = 2.6 10) (Fig
Nevertheless, kidney fibrosis is the end-stage renal disease (ESRD) and always be accompanied by the damage of ferroptosis-susceptible field, which is refered as iron metabolism, oxidative stress, inflammation, and autophagy [29,30,31]
US$ 21.55
US$ 26.16
US$ 24.66
US$ 28.22
